TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in short chain fatty acids production by gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cmax of Anastrozole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Anastrozole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Percent Change of Penile Curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of local and systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Concordance between actual HASS utilization vs HASS norms
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in depression symptoms (BDI-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in depression symptoms (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum and salivary melatonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of MRI images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of CA-HRE infections
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of HRE-culture positive community contacts
Endpoint domain: Adverse events/effects
Primary endpoint: C max: maximum observed plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T max: time of maximum observed plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1/2: apparent terminal half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC: area under the plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Anxiety Rating Scale (SIGH-A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression (CGI) Scale of Severity/Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility as assessed by the number of participant drop outs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence using 24 hour diet recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence assessed by serum carotenoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In vivo mRNA MxA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall Acne Scar Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective stress incontinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Treatment satisfaction rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of women not using urinary incontinence pads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Target Lesion Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite event of cardiovascular death/myocardial infarction/stroke/bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Fasting Plasma Glucose Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Phenotype of circulating T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of mRNAs related to PPARβ/δ gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive Symptoms (CES-D Score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fatal or non-fatal ischemic stroke or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Tolerability measured by interruptions/reductions of study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number and percent of subjects experiencing an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in event-related potentials (ERP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in clinical laboratory assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in parent-child bonding
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Confirmed overall hematologic response (OHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of volunteers positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory processing abilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of falls
Endpoint domain: Adverse events/effects
Primary endpoint: Haematology evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Biochemistry evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Waste Anesthetic Gas Measured by Parts Per Million Within PACU Caregiver's Breathing Zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waste Anesthetic Gas Measured by Parts Per Million Emanating From Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of the ISO-Gard Mask in Reducing Caregiver's Exposure to WAG-Percentage of Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of the ISO-Gard Mask in Reducing Caregiver's Exposure to WAG-Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pain interference in activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: GAF-F total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: BMI change over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Development of Unit-acquired Pressure Ulcers
Endpoint domain: Adverse events/effects
Primary endpoint: Renal protective properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Folate-related DNA endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophageal cancer specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: Cost for saving 1 quality-adjusted life year (QALY)
Endpoint domain: Resource use
Primary endpoint: Time to exhaustion during inspiratory endurance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Oxygen-Level Dependent (BOLD) Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysphagia assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Rhinoconjunctivitis Total Symptom Score (ARTSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (CR) rate
Endpoint domain: Mortality/survival
Primary endpoint: Best Overall Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Social Isolation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Level of Social Support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change Overall Well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Neuropathic Pain Symptom Inventory (NPSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Eccentricity of inferior vena cava transverse sections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total systemic exposure (AUCt and Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung exposure (AUCt and Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of iFR and FFR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of urine samples negative for opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: steady-state plasma pharmacokinetics of TP-434
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Oxygen Saturation in the Brain During Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Oxyhemoglobin Concentration in the Brain During Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total Hemoglobin Concentration in the Brain During Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Deoxy-Hemoglobin Concentration in the Brain During Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recovery process of AN
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in Ishak Fibrosis Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Glucose intolerance status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Regression of neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: DAS28-CRP Score Change at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: DAS28-CRP Score Change at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Post spinal puncture headache (PDPH)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in D-dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Clinical Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Thrombin Generation Assay - Endogenous Thrombin Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Count of Participants With Dose-Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Volume changes %
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of moderate to severe pain during movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of exercise in acute heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain management measured by the visual analog pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain management measured by quality of life score (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Death From Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Myocardial Infarction
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative Event Rate of Death From Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative Event Rate of Myocardial Infarction
Endpoint domain: Mortality/survival
Primary endpoint: Measures of peroxisomal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of psychosocial well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants With Immune-related Adverse Events (irAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Disease Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma tobramycin pharmacokinetic parameters (Cmax and AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vulvovaginal Atrophy Questionnaire (VVAQ) Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Western Ontario Shoulder Instability (WOSI) Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Body Fat (in kilograms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Muscle Mass (in kilograms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maximal strength (in kilograms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of ventilator associated pneumonia (VAP)
Endpoint domain: Adverse events/effects
Primary endpoint: Easiness of hysteroscopy introduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adequacy of uterine cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual pattern
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adolescent Recent Alcohol Intake Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adolescent Recent Alcohol Intake Amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food Insecurity
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Frequency of epileptic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pressure-pain algometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in functional impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: number and grade of acute allograft rejection episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Short physical performance battery (SPBB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burnout assessment score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: composite score of recurrent hospital admission due to HF or arrhythmias
Endpoint domain: Mortality/survival
Primary endpoint: heart transplantation/palliative care
Endpoint domain: Mortality/survival
Primary endpoint: Rate of expression of SLAM3 and MDR transcripts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events during transport
Endpoint domain: Adverse events/effects
Primary endpoint: self-reported intimate partner violence
Endpoint domain: Adverse events/effects
Primary endpoint: Dyspnea measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients presenting toxicity 3-4
Endpoint domain: Adverse events/effects
Primary endpoint: Time to a Successful Spontaneous Breathing Trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensive Care Unit Length of Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of CT performed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Satisfactory relief of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Solicited Adverse Events Up to 7 Days After Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Unsolicited Adverse Events After Each Dose
Endpoint domain: Adverse events/effects
Primary endpoint: PSA progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: radiological progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Successful Implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease activity in RA and SLE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in fasting fatty acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in cardiolipin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acceptability of Cookies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of concentration of leptospires in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bone block consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum prostate specific antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in MQC on Liver Biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event Free Survival (EFS) Using Kaplan-Meier
Endpoint domain: Mortality/survival
Primary endpoint: lipid benefits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sustained Virologic Response at Post-treatment Week 12 (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Treatment-Emergent Serious Adverse Events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Treatment-Emergent Adverse Events of Special Interest (TEAESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in health-related quality of life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Inflammatory skin responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Relief degree of tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of days to complete re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse reactions including allergic contact dermatitis (ACD)
Endpoint domain: Adverse events/effects
Primary endpoint: MoCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AVLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: WAIS-DST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Feasibility of G-CSF mobilized donor blood for transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post-operative Nausea and Vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Development of unacceptable toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax After the First and Last Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-infinity After the Last Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau After the Last Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American College of Rheumatology (ACR)20 Response Rate at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: IKDC-2000 Subjective Knee Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Vaccine Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccines safety
Endpoint domain: Adverse events/effects
Primary endpoint: number of receptors expressed by monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Histamine Release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Knee injury and Osteoarthritis Outcome Score scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FN rate
Endpoint domain: Adverse events/effects
Primary endpoint: Menstrual migraine attack frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Range Of Motion of Knee Joint (Flexion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range Of Motion of Knee Joint (Extension)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Css,max of anaprazole and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of anaprazole and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of anaprazole and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in immediate verbal attention after receiving treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in verbal digit working memory after receiving treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in verbal memory after receiving treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in visual memory after receiving treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes